

---

***In vitro* construction of yeast tRNA<sup>Asp</sup> variants: nucleotide substitutions and additions in T-stem and T-loop**

---

Philippe Carbon\* and Jean-Pierre Ebel

---

Laboratoire de Biochimie, Institut de Biologie Moléculaire et Cellulaire du CNRS, 15, rue René Descartes, 67084 Strasbourg cedex, France

---

Received December 30, 1986; Accepted February 12, 1987

---

**ABSTRACT**

A procedure for the construction of 3'-end labelled yeast tRNA<sup>Asp</sup> harboring substitutions or additions of any desired nucleotide in T-stem and T-loop (position 57 to 61) has been developed. This was done by *in vitro* enzymatic manipulations of the yeast tRNA<sup>Asp</sup> involving specific hydrolysis with RNases, phosphorylation and dephosphorylation with T4 polynucleotide kinase and ligation with T4 RNA ligase. Using this procedure we have replaced conserved or semi-conserved nucleotides located in position 57 to 61 of yeast tRNA<sup>Asp</sup>. We have also constructed different yeast tRNA<sup>Asp</sup> with eight bases instead of seven in T-loop. Further use of these tRNA<sup>Asp</sup> variants will be discussed with the help of the crystallographic three-dimensional structure.

**INTRODUCTION**

The three-dimensional structure of a tRNA molecule determines many of its biological activities. The crystallographic structure at high resolution of two elongator tRNAs from yeast, that of tRNA<sup>Phe</sup> (1-4) and that of tRNA<sup>Asp</sup> (5), are available at present. These tRNAs represent a model system for solution conformational compared studies. Chemical modifications of end-labelled RNAs followed by determination of the sites of modification by sequencing gel methodologies (6-7) has become a powerful approach for monitoring the solution structure of yeast tRNA<sup>Phe</sup> (8-9) and tRNA<sup>Asp</sup> (9). It is now well established that conserved or semi-conserved nucleotides play a central role in the three-dimensional conformation of the different tRNAs. Among the different domains in tRNAs, the T-loop and its extension in T-stem (the first base pair that closes the loop) is one of the most conserved region. For instance, it might be noticed the presence of the quasi-constant T $\psi$ CR sequence in all elongator tRNAs. It has been proposed that this part of T-loop might be involved in interactions with the ribosome (10-12) although their exact nature remains controversial (13-14). The T-loop has also a structural

role in tRNA dynamic by participating in the stabilization of the D-loop (15). Conformational studies of variants from yeast tRNA<sup>ASP</sup> or tRNA<sup>Phe</sup> harboring altered T-stem and loop should allow us to define the relative importance of the conserved or semi-conserved nucleotides in maintaining the local or overall structure of tRNAs.

For a few years it has become possible to manipulate in vitro nucleotide sequence of RNAs by combination of several enzymes, such as RNases, T4 polynucleotide kinase and T4 RNA ligase. Several kinds of tRNA variants were prepared by this approach and used for studies on the structure-function relationship (16-21). tRNA variants were equally used for studies of various parameters involved in anticodon-loop base modifications (22-26, for a review see ref. 26). However, replacement of nucleotides into tRNAs were generally limited to the anticodon-loop and to the 3'-terminal region. Recently, the construction of T.utilis tRNA<sup>Tyr</sup> containing deletions or substitutions of nucleotides in D-loop has been reported (27). In vitro tRNA reconstruction is currently the only available technique allowing preparation of tRNA variants carrying naturally modified nucleotides.

In this paper we describe a procedure for the in vitro construction of 3'-end labelled yeast tRNA<sup>ASP</sup> with alteration of nucleotide sequence in T-stem and T-loop (position 57 to 61 according to the numbering system of nucleotides in tRNAs (28)). Using this procedure we have created ten variants from yeast tRNA<sup>ASP</sup> harboring nucleotide substitutions or additions at position 57 to 61 in place of conserved or semi-conserved nucleotides. This report is the first describing a nucleotide substitution introduced in a stem using the T4-RNA ligase technology. Further solution structural mapping (using chemical or enzymatical probes) of these 3'-end labelled yeast tRNA<sup>ASP</sup> variants will be a useful step to better understand the role of conserved and semi-conserved nucleotides in the three-dimensional solution structure of yeast tRNA<sup>ASP</sup>.

## MATERIALS AND METHODS

### tRNA, oligonucleotides and enzymes

tRNA<sup>ASP</sup> from brewer's yeast was purified as described by Keith et al. (29).

Oligonucleotide HO<sup>AUG</sup>OH was from Sigma. The trinucleotide diphosphate HO<sup>AAU</sup>OH was obtained as described by Haumont et al. (24). Oligonucleotide HO<sup>UUU</sup><sub>p</sub> was prepared by limited alkaline hydrolysis at

60°C of poly U (Sigma) as described by Mc Farland and Borer (30).  $\text{HO}^{\text{UUU}}\text{p}$  was separated from the mixture on a 1 X 60 cm DEAE-Sephadex A25 column (Pharmacia Fine Chemicals) eluted using a linear gradient of triethylammonium bicarbonate pH 8.0 from 10 mM to 750 mM. The sample was desalted by rotary evaporation aided by the addition of methanol. Oligomer was subsequently desalted on a Sephadex G10 column equilibrated in water.

$\text{HO}^{\text{UUU}}\text{p}$  is then dephosphorylated by E.coli alkaline phosphatase (B.A.P) in the following conditions : 100  $A_{260}$   $\text{HO}^{\text{UUU}}\text{p}/\text{ml}$  in Tris HCl 50 mM pH 8.0 and 5 units of B.A.P/ $A_{260}$   $\text{HO}^{\text{UUU}}\text{p}$ . The reaction was performed at 37°C for 4h and  $\text{OH}^{\text{UUU}}\text{OH}$  was isolated by chromatography on a 2 ml DEAE-Sephadex A 25 column. The trimer was then concentrated and desalted as described before.

E.coli alkaline phosphatase, nuclease P1, spleen phosphodiesterase, T4 polynucleotide kinase and T4 polynucleotide kinase lacking the 3'-phosphatase activity were purchased from Boehringer Mannheim. Pancreatic RNase (RNase A) was obtained from Worthington and RNase T1, RNase T2 and RNase U2 from Calbiochem. T4 RNA ligase was obtained from Pharmacia. [ $\gamma^{32}\text{P}$ ]ATP (110 TBq/mmol) and [ $5^{32}\text{P}$ ]pCp(110 TBq/mmol) were purchased from Amersham.

#### Gel electrophoresis and recovery of RNA

After each enzymatic reaction the RNA fragments were usually purified by electrophoresis on denaturing polyacrylamide gel (P.A.G.E) containing 8.3 M urea ; 100 mM Tris-borate pH 8.3 and 3 mM EDTA. For preparative purpose, tRNA fragments were purified on thicker (2-4 mm polyacrylamide urea slab gels). The RNA bands were detected by ultraviolet shadowing (31), excised and eluted from the gel slices according to the crush and soak method (32). After a centrifugation step to remove acrylamide fragments, the RNA was ethanol precipitated. This step was repeated twice in order to remove SDS and impurities from the gel. Intermediates in variant tRNA construction and variant tRNAs were purified on thin (0.5 mm) polyacrylamide urea slab gels. In this case, the RNA bands were detected by autoradiography.

#### Preparation of yeast tRNA<sup>Asp</sup> fragments

##### Preparation of 5'-half and 3'-half tRNA

5'-half ( $\text{pU} \text{---} \overset{34}{\text{Gp}}$ ) and 3'-half ( $\overset{35}{\text{HO}}\text{U} \text{---} \overset{73}{\text{Gp}}$ )tRNA (Fig. 1, step 1) were prepared essentially as described by Carbon et al. (22).

##### Preparation of quarter tRNA

Quarter tRNA A :  $\overset{35}{\text{HO}}\text{U} \text{---} \overset{56}{\text{Cp}}$  was obtained by limited digestion of

3'-half tRNA by RNase A followed by preparative polyacrylamide gel electrophoresis (Fig.1, step 2). The standard reaction mixture contained 1 mg/ml (about 80  $\mu$ M) of 3'-half tRNA ; 50 mM Tris-HCl pH 7.5 ; 10 mM  $MgCl_2$  ; 100 mM NaCl and 0.5  $\mu$ g RNase A/mg RNA. The reaction was performed at 4°C for 30 min, then stopped by addition of an equal volume of phenol saturated with the hydrolysis buffer containing 2.5% (w/v) SDS and 0.34% (w/v) sucrose. After extraction, the RNA was ethanol precipitated.

Quarter tRNA B :  $\overset{35}{HO}U-\overset{57}{A}_p$ , C :  $\overset{35}{HO}U-\overset{58}{A}_p$ , D :  $\overset{59}{HO}U-\overset{73}{G}_p$  and E :  $\overset{58}{HO}A-\overset{73}{G}_p$  were obtained by partial hydrolysis of 3'-half tRNA with RNase U2 (Fig. 1, step 3). Enzymatic digestion was performed at 4°C for 20 mn in 20 mM ammonium acetate pH 4.5 containing 1 mg/ml of 3'half tRNA and 2 units of enzyme/mg RNA. The reaction was stopped by phenol extraction followed by preparative P.A.G.E.

Fragment F :  $\overset{60}{HO}U-\overset{73}{G}_p$  and fragment G :  $\overset{61}{HO}C-\overset{73}{G}_p$  were obtained by sequential resection of fragment D (or E) using spleen phosphodiesterase (S.P.D.E) (Fig.1, step 4). Experimental conditions were the following : 40  $\mu$ M fragment D ; 100 mM Imidazole-HCl pH 6.0 and 30  $\mu$ g/ml of S.P.D.E. Incubation was performed at 37°C for 15 min followed by phenol-extraction and P.A.G.E.

Fragment H :  $\overset{62}{HO}C-\overset{73}{G}_p$  was obtained by RNase A (Fig.1, step 5) partial hydrolysis of fragment D (40  $\mu$ M) in 20 mM Tris-HCl pH 7.5 ; 100 mM NaCl ; 10 mM  $MgCl_2$ . Hydrolysis was carried out at an RNase/RNA ratio of 1.25  $\mu$ g RNase A/ $\mu$ g RNA, for 30 min at 4°C. The reaction was stopped by phenol extraction and after ethanol precipitation, fragment H was purified by P.A.G.E.

The RNA fragments resulting from the above ribonuclease digestion were identified by their terminal nucleotides as described in (22) and by their nucleotide sequence using  $^{32}P$  and post-labelling techniques. Sequence analysis was performed essentially as described by Donis-Keller et al. (33).

#### 3'-end dephosphorylation of RNA fragments

Removal of the 3'-terminal phosphate from the 5'-half tRNA and from the quarters A,B,C,E,F,G,H was carried out by using the 3'-phosphatase activity of T4 polynucleotide kinase (34). The products at a concentration of 24  $\mu$ M in 100 mM Imidazole-HCl pH 6.0 ; 10 mM  $MgCl_2$  ; 3 mM DTE and 20  $\mu$ g/ml of BSA were incubated for 2h30 at 37°C with 50 units/ml of T4 polynucleotide kinase. The reaction was terminated by heating for 3 min at 65°C and the RNA was ethanol precipitated.

3'-end labelling of RNA fragments

The 3'-end labelling of the dephosphorylated fragments E,F,G and H (the products of step 1 in Fig.2A) was done by addition of [5'-<sup>32</sup>P] pCp to the 3'-hydroxyl group using T4 RNA ligase (step 2 in Fig.2A). Reaction mixture contained 30 μM fragment (300 pmoles) ; 10 μM [5'-<sup>32</sup>P]pCp (110 T Bq/mmoles) ; 100 μM ATP and 450 units/ml of T4 RNA ligase in 50 mM Hepes-KOH pH 7.5 ; 10 mM MgCl<sub>2</sub> ; 3.3 mM DTT ; 10 μg/ml BSA and 10% DMSO. Incubation was for 6h at 17°C and products were isolated by P.A.G.E and eluted from the gel. The 3'-end labelled fragments E,F,G,H were respectively denominated I,J,K,L.

Construction of 3'-end labelled yeast tRNA<sup>Asp</sup> variantsPreparation of 3'-end labelled quarter tRNA variants

Fragment J was joined (in the presence of T4 RNA ligase) with HO<sup>AUG</sup>OH or HO<sup>UUU</sup>OH ; fragment K was joined with HO<sup>AUG</sup>OH or HO<sup>AAU</sup>OH or HO<sup>UUU</sup>OH and fragment L was joined with HO<sup>UUU</sup>OH (Fig.2B). Prior to the ligation step, the 5'-end of fragments was phosphorylated (step 3 in Fig. 2B) in the following conditions : 1.5 μM of fragments J,K,L in 50 mM Tris-HCl pH 7.6 ; 10 mM MgCl<sub>2</sub> ; 5 mM DTT ; 10 μg/ml BSA ; 15 μM ATP were incubated with 500 units/ml of T4 polynucleotide kinase lacking the 3'-phosphatase activity. After 2h30 at 37°C the enzyme was inactivated by heating at 70°C for 3 min and the RNA was recovered by ethanol precipitation. The joining reaction (step 4 in Fig. 2B) of trinucleotides (OH<sup>UUU</sup>OH, HO<sup>AAU</sup>OH, HO<sup>AUG</sup>OH) was performed in 50 mM Hepes-KOH pH 7.5 ; 10 mM MgCl<sub>2</sub> ; 3,3 mM DTT ; 10 μg/ml BSA and 20% DMSO. Concentrations of the acceptor (trinucleotide), of ATP, of donor (5'-end phosphorylated fragment J,K,L) and T4 RNA ligase were 1.5 mM ; 1.5 μM ; 1.5 μM and 360 units/ml respectively. The reaction was performed at 17°C for 8h and the joined products were purified by P.A.G.E and eluted from the gel. The ligation products of trinucleotides HO<sup>AUG</sup>OH and HO<sup>UUU</sup>OH with fragment J were denominated J<sub>1</sub> and J<sub>2</sub> respectively. Addition products of trinucleotides HO<sup>AUG</sup>OH, HO<sup>AAU</sup>OH, HO<sup>UUU</sup>OH to fragment K were denominated K<sub>1</sub>, K<sub>2</sub>, K<sub>3</sub> respectively and the ligation product of HO<sup>UUU</sup>OH to fragment L was denominated L<sub>1</sub>.

Preparation of 3'-end labelled tRNA variants

5'-end phosphorylated fragments I, J<sub>1</sub>, J<sub>2</sub>, K<sub>1</sub>, K<sub>2</sub>, K<sub>3</sub> and L<sub>1</sub> were used as donors and 3'-end dephosphorylated fragments A, B, C as acceptors in different ligation reactions to form the various 3'-half tRNA variants (step 5 in Fig. 2C). The different combinations of donor

and acceptor are indicated in Fig. 2C. The reaction conditions were similar to those for the previous ligation step (step 4 in fig. 2B) except that the concentration of the donor, acceptor, ATP and T4 RNA ligase were 0.5  $\mu$ M, 16  $\mu$ M, 5  $\mu$ M and 180 units/ml respectively. Before the addition of T4 RNA ligase the mixture was incubated at 60°C for 5 mn and then cooled slowly to room temperature. After incubation at 17°C for 4h, enzyme was inactivated by heating at 70°C for 3 mn and the RNA was ethanol precipitated. The 3'-half tRNA variant was then submitted to a 5'-end phosphorylation (as described above) and ligated with the 3'-end dephosphorylated 5'-half tRNA to form tRNA-sized molecules (step 6 in fig. 2C). The ligation conditions were similar to those described above for the preparation of 3'-half tRNA variants except that the concentration of T4 RNA ligase was 40 units/ml. After incubation for 1h at 37°C, the various tRNA variants were purified by P.A.G.E and the 3'-end labelled tRNA<sup>ASP</sup> variants were localized by autoradiography. Electrophoretic mobility of these variants was compared with that of an authentic unlabelled yeast tRNA<sup>ASP</sup>, detected by U.V. shadowing.

#### Sequence analysis of 3'-end labelled tRNA<sup>ASP</sup> and of 3'-end labelled tRNA<sup>ASP</sup> variants

Sequence analysis was performed by the direct chemical method of Peattie (35). The unmodified yeast tRNA<sup>ASP</sup> was 3'-end labelled by addition of [5'-<sup>32</sup>P]pCp (110 TBq/nmole) with T4 RNA ligase to the 3'-termini of yeast tRNA<sup>ASP</sup>. Conditions of labelling were similar to those described above.


### RESULTS AND DISCUSSION

Using a combination of different enzymes : RNase T1, RNase A, RNase U2 and spleen phosphodiesterase under appropriate conditions it was possible to prepare various fragments of yeast tRNA<sup>ASP</sup>. These fragments and various trinucleotides were then used in conjunction with T4 polynucleotide kinase and T4 RNA ligase to reconstitute in vitro 3'-end labelled tRNA<sup>ASP</sup> variants having substitution or addition of nucleotides in T-stem (position 61) and in T-loop (position 57 to 60).

#### Experimental procedure

##### Preparation of yeast tRNA<sup>ASP</sup> fragments

Figure 1 shows the different hydrolyses used for preparing yeast tRNA<sup>ASP</sup> fragments. The products of each hydrolysis step were isolated by polyacrylamide gel electrophoresis. Due to the steric hindrance, it was not possible by enzymatic digestion of overall tRNA to obtain high yields



**Figure 1** : Scheme for the preparation of different tRNA fragments. Step 1, 3, 4 : limited digestion with RNase T1, RNase U2 and spleen phosphodiesterase (SPDE) respectively ; steps 2 and 5 : RNase A partial digestion. Letters A to E denote the different fragments used in this study.  $\blacktriangleright$  RNase T1 cleavage site ;  $\blacklozenge$  RNase U2 cleavage site ;  $\blacklozenge$  RNase A cleavage site ;  $\blacktriangleright$  SPDE cleavage site.

of RNA fragments generated by enzymatic cuts in T-loop. This problem was overcome by working on the isolated 3'-half tRNA. Under mild conditions, RNase T1 cleaves (22-29) predominantly (Fig.1 step 1) in the anticodon loop of yeast tRNA<sup>Asp</sup> between residues G34 and U35 (up to 75% - 80%) and in the 3'-extremity between residues G73 and C74 (up to 50%) generating the 5'-half tRNA and the 3'-half tRNA (with or without 3'-terminal CCA). Due to the persistence of T-stem structure in isolated 3'-half tRNA, (P. Romy et al., unpublished results) it was possible, using RNase A or




Figure 2 : Scheme for the construction of 3'-end labelled tRNA<sup>ASP</sup> variants.

A : 3'-end labelling of quarter tRNA<sup>ASP</sup>. E to H correspond to quarter tRNA described in Fig. 1. Step 1 : 3'-end dephosphorylation of RNA fragments with T4 polynucleotide kinase. Step 2 : 3'-end labelling using [5'-<sup>32</sup>P]pCp and T4 RNA ligase. The products of step 2 (fragments I to L) were isolated by P.A.G.E. \* position of [<sup>32</sup>P] label. B : Construction of 3'-end labelled quarter tRNA<sup>ASP</sup> variants. Prior to the ligation step 4, fragments J,K and L were 5'-end phosphorylated (step 3). The products of step 4 were isolated by P.A.G.E. Fragments J<sub>1</sub>,J<sub>2</sub>,K<sub>1</sub>,K<sub>2</sub>,K<sub>3</sub>,L<sub>1</sub> correspond to the extended fragments J,K,L. Trinucleotides AUG, UUU and AAU have hydroxyl groups at their 5' and 3'-ends. Altered nucleotides are underlined. C : Construction of 3'-end labelled 3'-half tRNA variants and 3'-end



labelled tRNA variants. Fragments A,B,C correspond to fragments described in Fig. 1. Prior to the ligation step 5, fragments A,B and C were 3'-end dephosphorylated and fragments I,J1,J2,K1 to K3 and L1 were 5'-end phosphorylated. The products of step 5 were not isolated by P.A.G.E. Prior to the ligation step 6, 5'-half tRNA was 3'-end dephosphorylated and 3'-half tRNA variants were 5'-end phosphorylated. The products of step 6 were isolated by P.A.G.E. ◆ denotes the different altered nucleotides.

RNase U2 partial hydrolysis (Fig.1 step 2 and 3 respectively) of the 3'-half tRNA (without the 3'-terminal CCA) to obtain various quarter tRNAs (fragments A,B,C,D,E in Fig.1) by enzymatic cuts in T-loop. Partial hydrolysis with RNase A (Fig.1 step 2) introduces multiple cleavages in the 3'-half tRNA. However, among multiple fragments, we could recover  $\text{HO}^{\text{35}}\text{U}^{\text{56}}\text{---Cp}$  as the major product (about 15% of recovery). Under mild conditions, RNase U2 (Fig.1 step 3) cleaves exclusively in the T-loop of the 3'-half tRNA between residues  $\text{A}_{57}$  and  $\text{A}_{58}$  and between residues  $\text{A}_{58}$  and  $\text{U}_{59}$  generating fragments B, C, D and E (see Fig.1). 80% of the starting material was recovered in these four RNase U2 hydrolysis products. Limited hydrolysis of fragment D with spleen phosphodiesterase (Fig.1 step 4) or with RNase A (Fig.1 step 5) was used to generate RNA fragments F, G and H corresponding to fragment D differently truncated in its 5'-part. Partial digestion of fragment D with spleen phosphodiesterase causes important recurrent cleavage, between  $\text{U}_{59}$  and  $\text{U}_{60}$ , between  $\text{U}_{60}$  and  $\text{C}_{61}$  generating RNA fragments F :  $\text{HO}^{\text{60}}\text{U}^{\text{73}}\text{---Gp}$  and G :  $\text{HO}^{\text{61}}\text{C}^{\text{73}}\text{---Gp}$ . Fragments F and G were obtained in good yields (about 20% of the starting material for each fragment). This yield is best explained if we consider the presence of a series of four cytosines that slow down dramatically the exonuclease activity of the enzyme (36). Limited digestion of fragment D with RNase A (Fig. 1 step 5) was used to generate fragment H corresponding to fragment D lacking the three 5'-terminal nucleotides. In early attempts, considerable difficulty was encountered in consistently obtaining a correct yield of fragment H. However the digestion described under Materials and Methods gave a final recovery of at least 25% of the starting fragment D. The reason for this RNase A preferential cleavage between residues  $\text{C}_{61}$  and  $\text{C}_{62}$  is not obvious. The absence of secondary structure in quarter tRNA D (15 nucleotide long) can explain the great difficulty in obtaining hydrolysis products of this fragment in high yields. Directed RNase H cleavage may be used as an alternative to possibly overcome this difficulty (37).

#### Construction of 3'-end labelled tRNA<sup>Asp</sup> variants

The RNA fragments resulting from the above ribonuclease diges-




Figure 3 : A : T-stem and loop consensus sequence of eukaryotic elongator tRNAs (44). N corresponds to any nucleotide ; R corresponds to a purine nucleotide ; no G indicates that G is never found at position 60. B,C,D,E : T-stem and loop sequences of tRNA<sup>ASP</sup> variants. B and C : tRNA variants with seven nucleotide long T-loop and harboring one (B) or two (C) nucleotide substitutions. D and E : tRNA variants with eight nucleotide long T-loop resulting from one nucleotide addition (D) or one nucleotide addition and one nucleotide substitution (E). Substituted or (and) added nucleotides are indicated by an arrow and fragments used in the ligation step 5 (see Fig. 2C) are indicated adjacent to the arrow.

tions as well as various trinucleotides were used to restructure the T-stem and T-loop of yeast tRNA<sup>ASP</sup> using the T4 RNA ligase technology. Figures 2A, B and C outline the procedure used to construct 3'-end labelled tRNA<sup>ASP</sup> variants. Additions or substitutions of nucleotides occurring in the ten tRNA<sup>ASP</sup> variants were indicated in Figures 3B, C, D and E. Synthesis of almost all of the 3'-end labelled tRNA<sup>ASP</sup> variants was essentially carried out in four ligation steps (step 2 in Fig. 2A, step 4 in Fig. 2B, step 5 and 6 in Fig. 2C) catalysed by the T4 RNA ligase. This enzyme catalyses the ATP-dependant formation of a phosphodiester bond between a donor molecule bearing a 5'-phosphate and an acceptor molecule bearing a 3'-hydroxyl group (38). Correct donor and acceptor molecules were obtained by using the 3'-end phosphatase activity of T4 polynucleotide kinase (34) and the 5'-kinase activity of T4 polynucleotide kinase devoid of the 3'-phosphatase activity (39). The yield of the different dephosphorylation steps was almost 90%, that of the phosphorylation was about 70%. No degradation of RNA fragments occurred during the incubation

with T4 polynucleotide kinase and it was not necessary to purify the products after phosphorylation or dephosphorylation steps.

The overall yield of such tRNA variant construction is low, therefore it is necessary to work with highly labelled molecules as starting material. The first ligation step (step 2 in Fig. 2A) using  $[5\text{'-}^{32}\text{P}]\text{pCp}$  and T4 RNA ligase introduces a  $^{32}\text{P}$  label at the 3'-end dephosphorylated quarters tRNAs E, F, G and H. Typical experiments yielded highly labelled fragments I, J, K and L ( $2.10^8$  dpm/ $\mu\text{g}$  of starting material). After purification by gel electrophoresis, fragments J, K, L were 5'-end phosphorylated with T4 polynucleotide kinase devoid of 3'-phosphatase activity (step 3 in Fig. 2B). Sequence alterations of yeast tRNA<sup>ASP</sup> was essentially performed in the second ligation step (step 4 in Fig. 2B). In this ligation, 5'-end phosphorylated fragments J, K, L (donor molecules) were joined to the 3'OH of various acceptor trinucleotides ( $\text{HO}^{\text{AUG}}\text{OH}$ ,  $\text{HO}^{\text{UUU}}\text{OH}$ ,  $\text{HO}^{\text{AAU}}\text{OH}$ ). At this step, the presence of a 3'-phosphate blocking group on donor molecules was required in order to prevent cyclisation or self addition of these donors. The resulting fragments were purified by gel electrophoresis. Figure 4A shows an example of the addition of K and J fragments to trinucleotides  $\text{HO}^{\text{UUU}}\text{OH}$  or  $\text{HO}^{\text{AUG}}\text{OH}$ . Yields in this step were 20-40% depending on acceptor nucleotide sequence. In addition  $\text{HO}^{\text{UUU}}\text{OH}$  is a poor acceptor as described by Romaniuk et al. (40). After the phosphorylation step 3 (Fig. 2B), the reaction products were not separated by P.A.G.E., explaining the presence of fragments K and J bearing no 5'-phosphates, as illustrated in Figure 4A. The third ligation step (step 5 in Fig. 2C) gave rise to the 3'-end labelled 3'-half tRNA variants. Before this ligation, the 3'-end labelled quarter tRNA variants  $\text{J}_1$ ,  $\text{J}_2$ ,  $\text{K}_1$ ,  $\text{K}_2$ ,  $\text{K}_3$ ,  $\text{L}_1$  (see Fig. 2B) were 5'-end phosphorylated using T4 polynucleotide kinase lacking the 3'-phosphatase activity in order to protect the 3'-phosphate. The RNA fragments were then annealed with 3'-end dephosphorylated fragments A, B or C (see Fig. 2C for the description of different combinations of donors and acceptors). The T-loop was subsequently sealed by incubation with T4 RNA ligase. The acceptor molecules (3'-end dephosphorylated fragments A, B or C) bear a hydroxyl group at their 5'-end in order to prevent their cyclisation or self addition. The mixture was then incubated with ATP and T4 polynucleotide kinase devoid of 3'-phosphatase activity. The 3'-end labelled 3'-half tRNA variants were annealed with the 3'-end dephosphorylated 5'-half tRNA and the anticodon loop was joined with a limited amount of T4 RNA ligase (Fig. 2C step 6). In this




Figure 4 :


A : Elongation of 5'-end phosphorylated fragments K and J by addition of trinucleotides  $\text{HO}^{\text{UUU}}\text{OH}$  or  $\text{HO}^{\text{AUG}}\text{OH}$  with T4 RNA ligase. Autoradiography of a 20% polyacrylamide gel. Lane 1 : fragment K +  $\text{HO}^{\text{UUU}}\text{OH}$  ; lane 2 : fragment K +  $\text{HO}^{\text{AUG}}\text{OH}$  ; lane 3 : fragment J +  $\text{HO}^{\text{UUU}}\text{OH}$  ; lane 4 : fragment J +  $\text{HO}^{\text{AUG}}\text{OH}$ .  $\rightarrow$  indicates the position of elongated product ;  $\circ\rightarrow$  indicates the position of residual 5'-end phosphorylated fragments K and J ;  $\bullet\rightarrow$  indicates the position of fragments K and J non phosphorylated at their 5'-end ; product indicated by  $\blacksquare\rightarrow$  corresponds probably to reversed action of T4 RNA ligase ; XC denotes the position of xylene cyanol marker dye.

B : Joining of the 3'-half containing altered T-stem ( $\text{C}_{61}$   $\text{U}_{61}$ ) and the 5'-half tRNA with T4 RNA ligase to obtain tRNA-sized molecule. Autoradiography of a 10% polyacrylamide gel. Lane 1 : ligation of 3'-end labelled 3'-half tRNA variant (product of  $\text{L}_1$  + C ligation, step 5 in Fig. 2C) with 5'-half tRNA ; lane 2 : native tRNA<sup>Asp</sup>, position (-) detected by U.V. shadowing ; lane 3 : unlabelled 3'-half tRNA (with 3'-terminal CCA), position (-) detected by U.V. shadowing :  $\dots\rightarrow$  indicates the position of residual 3'-end labelled 3'-half tRNA ;  $\bullet\rightarrow$  residual non 5'-end phosphorylated fragment  $\text{L}_1$  ;  $\circ\rightarrow$  residual 5'-end phosphorylated fragment  $\text{L}_1$  ;  $\blacksquare\rightarrow$  product of T4 RNA ligase reversal action ; XC denotes the position of xylene cyanol marker dye.

fourth and last ligation step the acceptor molecule (3'-end dephosphorylated 5'-half tRNA) bears a 5'-phosphate and a 3'-hydroxyl group. The annealing of the two tRNA halves prevents the circularisation of this acceptor (41). The final products were isolated by denaturing polyacrylamide gel electrophoresis. Example of final product purification is shown in Figure 4B. The presence of residual quarter tRNA is due to the fact that 3'-half tRNA variants are not isolated by P.A.G.E. The yield of ligation steps 5 and 6 (Fig. 2C) was about 45% and 75% respectively. As in the ligation step 4 (Fig. 2B and Fig. 4A), undesired RNA fragments appear in ligation steps 5 and 6. They are probably due to the reverse action of T4 RNA ligase (42) and contribute to the decrease in the yield of the ligation steps.

All yeast tRNA<sup>ASP</sup> variants (except for the tRNA variant C<sub>61</sub> → U<sub>61</sub>) migrated in the expected position on denaturing gels. All the different preparations of the T-stem variant C<sub>61</sub> → U<sub>61</sub> migrated more slowly than the products prepared by trinucleotide insertion in the T-loop. The tRNA<sup>ASP</sup> variants were obtained in radiochemical amounts and did not contain the 3'-terminal CpA<sub>OH</sub>. Overall yields of the final products were usually 0.5%-1% of the 3'-end labelled starting material (quarter fragment J, K, L). The limiting step in constructing these tRNA variants is the ligation of the trinucleotides to the fragments J, K, L (step 4 in Fig. 2B, 20-40% yield). Besides, its products being purified by P.A.G.E, this additional step strongly contributes to decrease the overall yield of the construction. One out of the ten 3'-end labelled tRNA<sup>ASP</sup> variants (containing an extra adenosine between residues A<sub>57</sub> and A<sub>58</sub>) was obtained essentially in three ligation steps. The yield of the final product with an extra adenosine residue in T-loop was generally 10-15% of the starting 3'-end labelled quarter I (see Fig. 2A and C for the construction). The yield of this construction is 10-20 fold as high as that of others. The explanation is found in the omission of ligation step 4 and purification step that follows.

The ten 3'-end labelled tRNA<sup>ASP</sup> variants were sequenced by the chemical method (35). Autoradiograms from sequencing six 3'-end labelled tRNA<sup>ASP</sup> variants and 3'-end labelled authentic yeast tRNA<sup>ASP</sup> are shown in Figure 5. The sequencing gels confirm that the sequence of each synthetic tRNA variant corresponds to the predicted sequence. All the data indicate that the tRNA C<sub>61</sub> → U<sub>61</sub> (Fig. 5B) has the same sequence as tRNA<sup>ASP</sup> except the cytosine to uridine base substitution in T-stem. The abnor-



**Figure 5 :** Chemical RNA sequencing of 3'-end labelled tRNA<sup>ASP</sup> variants. Autoradiography of sequencing gels. G : guanosine reaction ; A : adenosine major and guanosine minor reaction ; C : cytidine major and uridine minor reaction ; U : uridine major reaction. Authentic tRNA<sup>ASP</sup> : part A. tRNA variants : part B, U<sub>61</sub> → U<sub>61</sub> ; part C, A<sub>58</sub> → U<sub>58</sub> ; part D, A<sub>58</sub> → U<sub>58</sub> and U<sub>59</sub> → G<sub>59</sub> ; part E, extra U between residues 58 and 59 ; part F, extra A between residues 57 and 58 ; part G, U<sub>60</sub> → G<sub>60</sub> and extra A between residues 58 and 59. T-stem and loop of authentic yeast tRNA<sup>ASP</sup> : part H.

mal migration of this variant on polyacrylamide gel is probably due to an altered conformation of this molecule resulting from a G-U base pair at the end of the T-stem. An altered electrophoretic mobility of the same order has been reported for a species of *E.coli* 5S RNA where a cytidine to uridine transition transforms a G-C base pair to a G-U base pair (43).

**Sequence characteristics of tRNA<sup>ASP</sup> variants**

Nucleotide sequence of T-stem and T-loop of the ten tRNA<sup>ASP</sup> variants are shown in Figures 3B, C, D and E. tRNA<sup>ASP</sup> variants can be classified in four groups : tRNA with seven bases in T-loop harboring one (Fig. 3B) or two (Fig. 3C) nucleotide substitutions and tRNA<sup>ASP</sup> with

eight bases in T-loop resulting from one nucleotide addition (Fig. 3D) or from one nucleotide addition and one nucleotide substitution (Fig. 3E). The altered nucleotides were generally the conserved or semi-conserved nucleotides according to the consensus sequence of eukaryotic elongator tRNAs (44) (see Fig. 3A).

Four yeast tRNA<sup>ASP</sup> variants harbor each a single distinctive nucleotide substitution (Fig. 3B) :  $A_{58} \rightarrow U_{58}$ ,  $U_{59} \rightarrow A_{59}$ ,  $U_{60} \rightarrow G_{60}$ ,  $C_{61} \rightarrow U_{61}$ . Two of these replace the conserved nucleotides  $A_{58}$  (located in T-loop) and  $C_{61}$  (located in T-stem) by uridines. Another replaces  $U_{60}$  by a guanosine residue. In all authentic eukaryotic elongator tRNAs the nucleotide in this position is never a guanosine residue. In the fourth, the residue  $U_{59}$  (any nucleotide in this position in eukaryotic elongator tRNA) is replaced by an adenosine.

Two tRNA<sup>ASP</sup> variants carry each two adjacent nucleotides substitutions (Fig. 3C). In one of them, residues  $A_{57}$  (always a purine in eukaryotic elongator tRNAs) and  $A_{58}$  (always an adenosine in eukaryotic elongator tRNAs) are replaced by a uridine. In the other one, residues  $A_{58}$  and  $U_{59}$  are replaced by a uridine and a guanine respectively.

Two tRNA<sup>ASP</sup> variants show an additional nucleotide at two different locations in T-loop (Fig. 3D). In one variant an extra adenosine is inserted between residues  $A_{57}$  and  $A_{58}$  ; in the other one, an extra uridine is inserted between residues  $A_{58}$  and  $U_{59}$ . These nucleotide insertions yield tRNA<sup>ASP</sup> variants with an eight base T-loop instead of seven like in all authentic tRNAs.

Two other tRNA<sup>ASP</sup> variants also have an 8 base T-loop. These two tRNAs arise from the addition of an extra adenosine between residues  $A_{58}$  and  $U_{59}$  and from a substitution at two different locations : residue  $U_{59}$  is replaced by an adenosine in one variant and residue  $U_{60}$  is replaced by a guanosine in the other one.

### **Implications for conformational studies of yeast tRNA<sup>ASP</sup>**

Nucleotide additions or substitutions in T-loop may alter some tertiary interactions involved in three-dimensional structure of yeast tRNA<sup>ASP</sup>, especially at the level of the T-D loop contact. It is now possible to probe the solution structure of end-labelled RNAs using chemical or enzymatical probes. These approach need only limited amounts of [<sup>32</sup>P] end-labelled material. The direct conformational analysis in solution of 3'-end labelled yeast tRNA<sup>ASP</sup> variants will allow to stress the importance of tertiary interactions, involving conserved or semi-conserved nu-

cleotides, in maintaining the local or overall structure of tRNAs. In one instance the importance of the constant reverse Hoogsteen base pair T<sub>54</sub>-A<sub>58</sub> will be analysed by structural mapping of the tRNA<sup>ASP</sup> variant where the A<sub>58</sub> is replaced by a uridine (see Fig. 3B). A seven base T-loop may be required to allow the correct formation of reverse Hoogsteen T<sub>54</sub>-A<sub>58</sub> base pair. This issue and the role of the constant size of T-loop (always 7 nucleotides) might be elucidated by monitoring the solution structure of tRNA<sup>ASP</sup> variants with eight nucleotides in T-loop (see Figs. 3D and 3E). In the tRNA<sup>ASP</sup> variant where the constant C<sub>61</sub> was replaced by a uridine, the hydrogen bond (p<sub>60</sub>-C<sub>61</sub>) that units phosphate 60 (phosphate located between C<sub>61</sub> and C<sub>62</sub>) with the N4 atom of the C<sub>61</sub> (9) is impaired. Conformational studies of this variant will allow to determine the exact role of the p<sub>60</sub>-C<sub>61</sub> hydrogen bond. A guanosine residue is never found at position 60 in all eukaryotic elongator tRNAs (see Fig. 3A). Conformational analysis of variant tRNA where U<sub>60</sub> is replaced by a G should help understand the reason for this absence.

Preparation of tRNA<sup>ASP</sup> variants according to the rationale described in this paper as well as structural analysis in solution (P. Romby et al. unpublished results) constitute an additional approach to conformational analysis of tRNAs.

#### ACKNOWLEDGEMENTS

We are grateful to A. Krol and P. Romby for improvements and critical review of the manuscript. We also thank G. Keith and E. Haumont for the generous gifts of yeast tRNA<sup>ASP</sup> and trinucleotide AAU.

\*To whom correspondence should be addressed

#### REFERENCES

1. Quigley, G.Y., Wang, A., Seeman, N.C., Suddath, F.L., Rich, A., Sussman, J.L. and Kim, S.H. (1975). Proc. Natl. Acad. Sci. (USA) 72, 4866-4870.
2. Jack, A., Ladner, J.E. and Klug, A. (1976). J. Mol. Biol. 108, 619-649.
3. Stout, C.D., Mizuno, M., Rao, S.T., Swaminathan, P., Rubin, J., Brennan, T. and Sundaralingam, M. (1978). Acta Crystallogr. 354, 1529-1540.
4. Sussman, J.L., Holbrook, S.R., Warrant, R.W., Church, G.M. and Kim, S.H. (1978). J. Mol. Biol. 123, 607-630.
5. Westhof, E., Dumas, P. and Moras, D. (1985). J. Mol. Biol. 184, 119-145.
6. Peattie, D.A. and Gilbert, W. (1980). Proc. Natl. Acad. Sci. (USA) 77, 4679-4682.



7. VTassov, V.V., Giegé, R. and Ebel, J.P. (1981). *Eur. J. Biochem.* 119, 51-59.
8. Holtbrook, S.R. and Kim, S.H. (1983). *Biopolymers* 22, 1145-1166.
9. Romby, P., Moras, D., Bergdoll, M., Dumas, P., VTassov, V.V., Westhof, E., Ebel, J.P. and Giegé, R. (1985). *J. Mol. Biol.* 184, 455-471.
10. Davenloo, P., Sprinzl, M. and Cramer, F. (1979). *Biochemistry* 18, 3189-3199.
11. Gassen, H.G. (1980). *Prog. Nucleic Acid Res. Mol. Biol.* 24, 57-86.
12. Schwarz, V., Menzel, H.M. and Gassen, H.G. (1976). *Biochemistry* 15, 2484-2490.
13. Pace, B., Matthews, E.A., Johnson, K.D., Cantor, C.R. and Pace, N.R. (1982). *Proc. Natl. Acad. Sci. (USA)* 79, 36-40.
14. Helk, B. and Sprinzl, M. (1985). *Nucleic Acids Res.* 13, 6283-6298.
15. Moras, D., Dock, A.C., Dumas, P., Westhof, E., Romby, P., Ebel J.P. and Giegé, R. (1986). *Proc. Natl. Acad. Sci.* 83, 932-936.
16. Bruce, A.G. and Uhlenbeck, O.C. (1982). *Biochemistry* 21, 3921-3926.
17. Uemura, H., Imai, M., Ohtsuka, E., Ikehara, M. and SOTT, D. (1982). *Nucleic Acids Res.* 10, 6531-6539.
18. Schulman, L.H. and Pelka, H. (1983). *Proc. Natl. Acad. Sci. (USA)* 80, 6755-6759.
19. Doi, T., Yamane, A., Matsugi, J., Ohtsuka, E. and Ikehara, M. (1985). *Nucleic Acids Res.* 13, 3685-3697.
20. Bare, L.A. and Uhlenbeck, O.C. (1986). *Biochemistry* 25, 5825-5830.
21. Bruce, A.G., Atkins, J.F. and Gesteland, R.F. (1986). *Proc. Natl. Acad. Sci. (USA)* 83, 5062-5065.
22. Carbon, P., Haumont, E., de Henau, S., Keith, G and Grosjean, H. (1982) *Nucleic Acids Res.* 10, 3715-3732.
23. Carbon, P., Haumont, E., de Henau, S., Fournier, M., and Grosjean, H. (1983). *EMBO J.* 2, 1093-1097.
24. Haumont, E., Fournier, M., de Henau, S. and Grosjean, H. (1984). *Nucleic Acids Res.* 12, 2705-2715.
25. Droogmans, L., Haumont, E., de Henau, S. and Grosjean, H. (1986). *EMBO J.* 5, 1105-1109.
26. Grosjean, H., Haumont, E., Droogmans, L., Carbon, P., Fournier, M., de Henau, S., Doi, T., Keith, G., Gangloff, J., Kretz, K. and Trewyn, R. (1987) ; in *Phosphorus chemistry directed towards Biology*. Eds W.J. Stec and M. Wiewiorowski. Elseviers North Holland., submitted.
27. Ohyama, T., Nishikawa, K. and Takemura, S. (1986). *J. Biochem.* 99, 859-866.
28. Sprinzl, M. and Gauss, D.M. (1984). *Nucleic Acids Res.* 12 r1-r57
29. Keith, G., Gangloff, J. and Dirheimer, G. (1971). *Biochimie* 53, 123-125.
30. Mc. Farland, G.D. and Borer, P.N. (1979). *Nucleic Acids Res.* 7, 1067-1080.
31. Hassur, S.M. and Whithlock, J.R. (1974). *Anal. Biochem.* 59, 162-164.
32. Maxam, A.M. and Gilbert, W. (1977). *Proc. Natl. Acad. Sci. (USA)* 74, 560-564.
33. Donis-Keller, H., Maxam, A.M. and Gilbert, W. (1977). *Nucleic Acids Res.* 4, 2527-2538.
34. Cameron, V. and Uhlenbeck, O.C. (1977). *Biochemistry* 16 5120-5126
35. Peattie, D. (1979). *Proc. Natl. Acad. Sci. (USA)* 76, 1760-1764.
36. Barrell, B.G. (1971) in *Procedures in Nucleic Acid Research*, Cantoni, G.L. and Davies, D.R., Eds vol. 2 pp. 751-812, Harper and Row, N.Y.
37. Donis-Keller, H. (1979) *Nucleic Acids Res.* 7, 179-192

38. Uhlenbeck, O.C. and Gumpert, R.I. (1982) in *The Enzymes* (BOYER, P., ed.) 3rd edn vol. XV pp. 31-58, Academic Press.
39. Cameron, V., Soltis, D. and Uhlenbeck, O.C. (1978). *Nucleic Acids Res.* 5, 825-833.
40. Romanuk, E., Mc. Laughlin, L.W., Neilson, T. and Romaniuk, P.J. (1982). *Eur. J. Biochem.* 125, 639-643.
41. Bruce, A.G. and Uhlenbeck, O.C. (1978). *Nucleic Acids Res.* 5, 3655-3677.
42. Krug, M. and Uhlenbeck, O.C. (1982). *Biochemistry* 21, 1858-1864.
43. Digweed, M., Kumagai, I., Pieler, T. and Erdmann, V.A. (1982). *Eur. J. Biochem.* 127, 531-537.
44. Grosjean, H., Cedergren, R.J. and Mc. Kay, W. (1982). *Biochimie* 64, 387-397.